Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure)

Translated title of the contribution: Lipoic acid α-potential modulator of insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

S. Jacob, D. E. Clancy, A. L. Schiemann, I. Simon, W. I. Jung, Erik J Henriksen, H. J. Tritschler, H. J. Augustin, G. J. Dietze

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thioctic acid, also known as alpha lipoic acid (ALA), a naturally occuring compound, is frequently used for the treatment of diabetic polyneuropathy and was shown to be a safe and reliable drug. Experimental studies revealed enhanced glucose transport and utilization in different animal models. Therefore, it was of interest to investigate whether ALA is also capable to stimulate glucose disposal in clinical conditions of reduced insulin sensitivity, such as NIDDM. A case report supported the hypothesis, and pilot studies were initiated, in which well controlled Type 2 diabetics received ALA (1.000 mg/500 ml NaCl; or vehicle only) during a hyperinsulinemic glucose-clamp (placebo controlled study) or 500 ml ALA/d over 10 d in an open uncontrolled study. While the acute administration of vehicle had no significant effect on insulin sensitivity (MCR1 3,6 ± 0,21 vs. MCR2 4,01 ± 0,19 ml/kg/min), the infusion of ALA resulted in a marked increase of glucose disposal by about 50% (MCR1 3,91 ± 0,6 vs. MCR2 5,89 ± 0,8 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). The ten day treatment of type II diabetics with ALA enhanced insulin-stimulated whole body glucose disposal by about 30% (MCR1 2,47 ± 0,28 vs. MCR2 3,15 ± 0,35 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). Meanwhile other groups have confirmed these observations. In conclusion, the present data indicate that parenteral administration of thioctic acid enhances insulin-stimulated glucose disposal in NIDDM. Animal studies suggest that the compound increases insulin-stimulated glucose transport activity, non-oxidative glucose disposal and glucose oxidation in peripheral tissues, such as skeletal muscle.

Original languageGerman
Pages (from-to)64-70
Number of pages7
JournalDiabetes und Stoffwechsel
Volume5
Issue number3 SUPPL.
StatePublished - 1996
Externally publishedYes

Fingerprint

Thioctic Acid
Type 2 Diabetes Mellitus
Insulin Resistance
Glucose
Insulin
Glucose Clamp Technique
Diabetic Neuropathies
Skeletal Muscle
Animal Models
Placebos
Therapeutics

Keywords

  • insulin resistance
  • non-insulin-dependent diabetes mellitus
  • thioctic/lipoic acid

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Jacob, S., Clancy, D. E., Schiemann, A. L., Simon, I., Jung, W. I., Henriksen, E. J., ... Dietze, G. J. (1996). Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure). Diabetes und Stoffwechsel, 5(3 SUPPL.), 64-70.

Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure). / Jacob, S.; Clancy, D. E.; Schiemann, A. L.; Simon, I.; Jung, W. I.; Henriksen, Erik J; Tritschler, H. J.; Augustin, H. J.; Dietze, G. J.

In: Diabetes und Stoffwechsel, Vol. 5, No. 3 SUPPL., 1996, p. 64-70.

Research output: Contribution to journalArticle

Jacob, S, Clancy, DE, Schiemann, AL, Simon, I, Jung, WI, Henriksen, EJ, Tritschler, HJ, Augustin, HJ & Dietze, GJ 1996, 'Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure)', Diabetes und Stoffwechsel, vol. 5, no. 3 SUPPL., pp. 64-70.
Jacob, S. ; Clancy, D. E. ; Schiemann, A. L. ; Simon, I. ; Jung, W. I. ; Henriksen, Erik J ; Tritschler, H. J. ; Augustin, H. J. ; Dietze, G. J. / Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure). In: Diabetes und Stoffwechsel. 1996 ; Vol. 5, No. 3 SUPPL. pp. 64-70.
@article{ecdec0e369d845ff82dc88c10067c656,
title = "Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure)",
abstract = "Thioctic acid, also known as alpha lipoic acid (ALA), a naturally occuring compound, is frequently used for the treatment of diabetic polyneuropathy and was shown to be a safe and reliable drug. Experimental studies revealed enhanced glucose transport and utilization in different animal models. Therefore, it was of interest to investigate whether ALA is also capable to stimulate glucose disposal in clinical conditions of reduced insulin sensitivity, such as NIDDM. A case report supported the hypothesis, and pilot studies were initiated, in which well controlled Type 2 diabetics received ALA (1.000 mg/500 ml NaCl; or vehicle only) during a hyperinsulinemic glucose-clamp (placebo controlled study) or 500 ml ALA/d over 10 d in an open uncontrolled study. While the acute administration of vehicle had no significant effect on insulin sensitivity (MCR1 3,6 ± 0,21 vs. MCR2 4,01 ± 0,19 ml/kg/min), the infusion of ALA resulted in a marked increase of glucose disposal by about 50{\%} (MCR1 3,91 ± 0,6 vs. MCR2 5,89 ± 0,8 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). The ten day treatment of type II diabetics with ALA enhanced insulin-stimulated whole body glucose disposal by about 30{\%} (MCR1 2,47 ± 0,28 vs. MCR2 3,15 ± 0,35 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). Meanwhile other groups have confirmed these observations. In conclusion, the present data indicate that parenteral administration of thioctic acid enhances insulin-stimulated glucose disposal in NIDDM. Animal studies suggest that the compound increases insulin-stimulated glucose transport activity, non-oxidative glucose disposal and glucose oxidation in peripheral tissues, such as skeletal muscle.",
keywords = "insulin resistance, non-insulin-dependent diabetes mellitus, thioctic/lipoic acid",
author = "S. Jacob and Clancy, {D. E.} and Schiemann, {A. L.} and I. Simon and Jung, {W. I.} and Henriksen, {Erik J} and Tritschler, {H. J.} and Augustin, {H. J.} and Dietze, {G. J.}",
year = "1996",
language = "German",
volume = "5",
pages = "64--70",
journal = "Diabetes und Stoffwechsel",
issn = "1861-7603",
publisher = "Verlag Kirchheim and Co. GmbH",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Verbesserung der Glucoseverwertung bei Patienten mit Typ-II-Diabetes mellitus unter α-Liponsaure (Thioctsaure)

AU - Jacob, S.

AU - Clancy, D. E.

AU - Schiemann, A. L.

AU - Simon, I.

AU - Jung, W. I.

AU - Henriksen, Erik J

AU - Tritschler, H. J.

AU - Augustin, H. J.

AU - Dietze, G. J.

PY - 1996

Y1 - 1996

N2 - Thioctic acid, also known as alpha lipoic acid (ALA), a naturally occuring compound, is frequently used for the treatment of diabetic polyneuropathy and was shown to be a safe and reliable drug. Experimental studies revealed enhanced glucose transport and utilization in different animal models. Therefore, it was of interest to investigate whether ALA is also capable to stimulate glucose disposal in clinical conditions of reduced insulin sensitivity, such as NIDDM. A case report supported the hypothesis, and pilot studies were initiated, in which well controlled Type 2 diabetics received ALA (1.000 mg/500 ml NaCl; or vehicle only) during a hyperinsulinemic glucose-clamp (placebo controlled study) or 500 ml ALA/d over 10 d in an open uncontrolled study. While the acute administration of vehicle had no significant effect on insulin sensitivity (MCR1 3,6 ± 0,21 vs. MCR2 4,01 ± 0,19 ml/kg/min), the infusion of ALA resulted in a marked increase of glucose disposal by about 50% (MCR1 3,91 ± 0,6 vs. MCR2 5,89 ± 0,8 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). The ten day treatment of type II diabetics with ALA enhanced insulin-stimulated whole body glucose disposal by about 30% (MCR1 2,47 ± 0,28 vs. MCR2 3,15 ± 0,35 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). Meanwhile other groups have confirmed these observations. In conclusion, the present data indicate that parenteral administration of thioctic acid enhances insulin-stimulated glucose disposal in NIDDM. Animal studies suggest that the compound increases insulin-stimulated glucose transport activity, non-oxidative glucose disposal and glucose oxidation in peripheral tissues, such as skeletal muscle.

AB - Thioctic acid, also known as alpha lipoic acid (ALA), a naturally occuring compound, is frequently used for the treatment of diabetic polyneuropathy and was shown to be a safe and reliable drug. Experimental studies revealed enhanced glucose transport and utilization in different animal models. Therefore, it was of interest to investigate whether ALA is also capable to stimulate glucose disposal in clinical conditions of reduced insulin sensitivity, such as NIDDM. A case report supported the hypothesis, and pilot studies were initiated, in which well controlled Type 2 diabetics received ALA (1.000 mg/500 ml NaCl; or vehicle only) during a hyperinsulinemic glucose-clamp (placebo controlled study) or 500 ml ALA/d over 10 d in an open uncontrolled study. While the acute administration of vehicle had no significant effect on insulin sensitivity (MCR1 3,6 ± 0,21 vs. MCR2 4,01 ± 0,19 ml/kg/min), the infusion of ALA resulted in a marked increase of glucose disposal by about 50% (MCR1 3,91 ± 0,6 vs. MCR2 5,89 ± 0,8 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). The ten day treatment of type II diabetics with ALA enhanced insulin-stimulated whole body glucose disposal by about 30% (MCR1 2,47 ± 0,28 vs. MCR2 3,15 ± 0,35 ml/kg/min, p ≤ 0,05, Wilcoxon-Rank-Sumtest). Meanwhile other groups have confirmed these observations. In conclusion, the present data indicate that parenteral administration of thioctic acid enhances insulin-stimulated glucose disposal in NIDDM. Animal studies suggest that the compound increases insulin-stimulated glucose transport activity, non-oxidative glucose disposal and glucose oxidation in peripheral tissues, such as skeletal muscle.

KW - insulin resistance

KW - non-insulin-dependent diabetes mellitus

KW - thioctic/lipoic acid

UR - http://www.scopus.com/inward/record.url?scp=0030499210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030499210&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 64

EP - 70

JO - Diabetes und Stoffwechsel

JF - Diabetes und Stoffwechsel

SN - 1861-7603

IS - 3 SUPPL.

ER -